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Background
Growing prevalence of TB and the emergence of XDR-
TB have stimulated substantial efforts to develop better
vaccines for TB. Recent researches have shown that
some of the antigenic proteins and fusion of different
proteins produced by Mycobacterium tuberculosis can
give protection in animal models when administrated
with specific adjuvants. In the present study, we
explored the use HBcag-VLPs for delivery of tuberculo-
sis antigens.
Methods
HBcVLPs bearing ESAT-6 and CFP-10 were constructed
using PCR and recombinant DNA methods. Proteins
were expressed in E. coli and purified. VLPs formation
was confirmed with TEM. BALB/c mice were immu-
nized with VLPs and controls without any adjuvants.
Sera were analysed for antibody responses (ELISA).
Splenocytes were cultured and restimulated with puri-
fied antigens and CF (culture filtrate) of M.tb. The cell
proliferation was measured using cell proliferation assay
kit and the culture supernatants were analysed for IL-2,
IFN-g and TNF.
Results
The recombinant VLP induces preferentially a Th1-type
immune response against mycobacterial antigen even
though Th2 has been reported as the predominant
response in BALB/c mice. IFN-g, IL-2, TNF and prolif-
eration were significantly higher in mice immunised
with HBcVLPs-M. tuberculosis antigen. Restimulation
with mycobacterial CF also produced the same effect.
Conclusion
The humoral and cellular responses suggest that the
VLP containing fusion constructs generated immune
response in a Th1 dependent manner. By virtue of its
self-adjuvant nature, HBc VLPs are a better vaccine
delivery system for use with newer antigens identified in
t h ec o u r s eo fr e c e n td e v e l o p m e n t si ns u b u n i tp r o t e i n
vaccine research in tuberculosis.
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